FDA/CDC

FDA expands atogepant approval to include chronic migraine


 

The Food and Drug Administration has approved an expanded indication for atogepant (Qulipta, Abbvie) to include prevention of chronic migraine in adults. The approval makes atogepant the first, and only, oral calcitonin gene-related peptide receptor antagonist approved to prevent migraine across frequencies, including episodic and chronic, the company said in a news release.

The FDA initially approved atogepant in 2021 for the prevention of episodic migraine in adults.

Once-daily atogepant is available in three doses – 10 mg, 30 mg, and 60 mg – for prevention of episodic migraine. However, only the 60-mg dose of medication is indicated for the preventive treatment of chronic migraine.

The expanded indication in chronic migraine is based on positive results of the phase 3 PROGRESS trial, which evaluated atogepant in more than 700 adults with chronic migraine.

The trial met the primary endpoint of statistically significant reduction from baseline in mean monthly migraine days with atogepant compared with placebo across the 12-week treatment period.

Treatment with atogepant also led to statistically significant improvements in all six secondary endpoints, including the proportion of patients that achieved at least a 50% reduction in mean monthly migraine days across 12 weeks and improvements in function and reduction in activity impairment caused by migraine.

The efficacy results are consistent with those in the ADVANCE episodic migraine trial.

The overall safety profile of atogepant is consistent with the episodic migraine patient population, with the most common adverse events including constipation, nausea, and fatigue/sleepiness.

“The FDA approval is an important milestone, providing those most impacted by migraine with a new, safe, and effective treatment option in a convenient, once-daily pill,” Peter McAllister, MD, director of the New England Center for Neurology and Headache, Stamford, Conn., said in the news release.

The data demonstrate that atogepant “helps reduce the burden of migraine by delivering improvements in function, with high response rates and sustained efficacy over 12 weeks. These are critical factors neurologists and headache specialists consider when prescribing a treatment option, particularly for those with chronic migraine,” Dr. McAllister added.

A version of this article originally appeared on Medscape.com.

Recommended Reading

CBT may improve comorbid posttraumatic headache, PTSD
MDedge Internal Medicine
Digital therapy may ‘rewire’ the brain to improve tinnitus
MDedge Internal Medicine
Recommending exercise for migraine: Just do it
MDedge Internal Medicine
Postconcussion symptoms tied to high risk of depression
MDedge Internal Medicine
Remote electrical neuromodulation device helps reduce migraine days
MDedge Internal Medicine
How a concussion led a former football player/WWE star to a pioneering neuroscience career
MDedge Internal Medicine
‘Quick, affordable’ test helps predict CGRP response for migraine
MDedge Internal Medicine
Migraine after concussion linked to worse outcomes
MDedge Internal Medicine
Cluster, migraine headache strongly linked to circadian rhythm
MDedge Internal Medicine
Atogepant prevents episodic migraine in some difficult-to-treat cases
MDedge Internal Medicine